Arlington Asset Investment Corp.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. Rock Tonkel Jr., CPA
- Full Time Employees
- 9
- Sector
- Real Estate
- Industry
- REIT - Mortgage
- Address
- Potomac Tower Arlington VA United States of America 22209
- IPO Date
- Dec 23, 1997
- CIK
- 0001209028
- Website
- arlingtonasset.com
- Similar Companies
- Business
- Arlington Asset Investment Corp. is a mortgage real estate investment trust primarily engaged in investing in mortgage-related and residential real estate assets. The company’s core investment portfolio includes mortgage servicing rights (MSR) related assets, credit investments secured by residential or commercial real estate or non-agency mortgage-backed securities (MBS), single-family residential rental properties, and agency MBS guaranteed by government-sponsored enterprises such as Fannie Mae and Freddie Mac. Arlington Asset funds its investments mainly through short-term financing arrangements like repurchase agreements and employs hedging strategies to manage interest rate sensitivity related to its borrowing costs and MBS portfolio. Headquartered in McLean, Virginia, and founded in 1997, Arlington operates predominantly within the U.S. residential mortgage and real estate sectors. In recent major developments, Arlington Asset Investment Corp. announced a definitive merger agreement with Ellington Financial Inc. in May 2023. This strategic transaction, completed by the end of 2023, enhanced the combined company’s scale, liquidity, and capital market access, aligning complementary mortgage servicing rights portfolios with an expected pro forma equity capital base exceeding $1.5 billion. The merger aims to drive earnings accretion, operational efficiencies, and long-term growth by leveraging Arlington’s relatively low leverage and Ellington’s existing management platform and expertise. Additionally, Arlington has focused recently on preserving capital, managing liquidity, and capitalizing on market opportunities amid evolving conditions. It has also repurchased shares and successfully closed sales of single-family residential properties as part of its portfolio management. Arlington Asset targets institutional investors seeking long-term returns through exposure to diversified mortgage-related assets. Its business segments include mortgage servicing rights financing, credit investments, single-family rental properties, and agency MBS investments across the United States. The company elected to be taxed as a REIT in 2019, emphasizing a multi-channel investment strategy beyond its historical agency MBS focus. Through its partnership with Ellington Financial, Arlington is positioned to leverage combined operational strengths and expanded financial resources to capitalize on growing opportunities in residential real estate finance and credit markets. This comprehensive strategic repositioning and merger combine Arlington’s deep expertise in mortgage servicing rights and residential real estate investment with Ellington’s diversified financial asset platform, reflecting a significant shift to broader mortgage credit sectors and scalable growth. The company’s headquarters are located in the Washington, D.C. metropolitan area, from which it manages its diverse real estate investment trust portfolio. Overall, Arlington Asset Investment Corp. operates as a specialized mortgage REIT focused on delivering shareholder value through diversified mortgage-related investments, supported by recent transformative corporate actions including the merger with Ellington Financial Inc. and active portfolio management initiatives in U.S. residential mortgage markets.
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference®
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling
Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026